Alumis Inc.
ALMS
Kedudukan dalam Saham
#9912
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Harga Saham
$6.78
Modal Pasaran
$877.57M
Perubahan (1 hari)
1.19%
Perubahan (1 tahun)
198.68%
Negara
US
Perdagangan Alumis Inc. (ALMS)
Kategori
Healthcare
Sejarah harga saham bagi Alumis Inc. (ALMS)
Harga penutupan tertinggi: $2.34 pada 2025-05-01
Harga penutupan terendah: $21.58 pada 2023-05-01
Harga penutupan terendah: $21.58 pada 2023-05-01
Sejarah harga saham Alumis Inc. dari 2023 hingga 2026
Prestasi harga saham tahunan
| Tahun | Prestasi |
|---|---|
| 2025 | -35.06% |
| 2024 | -49.49% |
| 2023 | 0.00% |
Harga saham bagi syarikat atau pesaing serupa
| Syarikat | Harga saham | Perubahan 1thn% | Negara |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $137.75 | -3.72% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
